Wataru Inui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wataru Inui has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Keisuke Inagaki
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
1 shared publication - Ken Sugimoto
First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan
1 shared publication - Kenichi Takahashi
First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan
1 shared publication - Kiichi Sugiura
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
1 shared publication - Mihoko Yamade
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
1 shared publication - Moriya Iwaizumi
Department of Laboratory Medicine Hamamatsu University School of Medicine Shizuoka Japan
1 shared publication
Latest Publications
- Open Access
- 29 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2609
Real-World Evaluation of an AI-Assisted Diagnostic Support System for Early Gastric Cancer: Diagnostic Performance, Confidence Stratification, and Determinants of False-Positive Diagnosis
Background/Objectives: Artificial intelligence (AI)-assisted endoscopy has shown high sensitivity for early gastric cancer detection; however, false-positive diagnoses remain a clinical challenge. This study aimed to evaluate the real-world diagnostic performance of a commercially available AI system and to identify factors associated with false-positive diagnoses, focusing on repeated AI evaluations and confidence stratification. Methods: This single-center retrospective study included 47 patients with 89 localized gastric lesions evaluated between March 2024 and March 2025. Endoscopic examinations were performed under white-light, non-magnified observation with repeated AI assessments of each lesion. The rates of “Consider biopsy” (B) judgments were calculated. Lesions with a B judgment rate of ≥50% were defined as AI-positive and classified into four AI confidence categories. Diagnostic performance was assessed using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Factors associated with false-positive diagnoses were analyzed using penalized logistic regression. Results: The AI system demonstrated a sensitivity of 97.6% and an NPV of 95.7%, with a specificity of 45.8%. Pathology-positive rates decreased stepwise across the four AI confidence categories (p < 0.001). Among AI-positive lesions, low regional reproducibility, lesion size ≥ 30 mm, scar, and erosion were independently associated with false-positive diagnoses. In analyses restricted to non-neoplastic lesions, lesion size ≥ 30 mm remained significantly associated with false-positive diagnosis. Conclusions: In real-world clinical practice, a commercially available AI system provides high sensitivity for early gastric cancer detection. Incorporating confidence stratification and regional reproducibility into clinical decision-making may enhance the effective use of AI-assisted endoscopic diagnosis beyond binary interpretations.
- 29 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2609
Open AccessReal-World Evaluation of an AI-Assisted Diagnostic Support System for Early Gastric Cancer: Diagnostic Performance, Confidence Stratification, and Determinants of False-Positive Diagnosis
Background/Objectives: Artificial intelligence (AI)-assisted endoscopy has shown high sensitivity for early gastric cancer detection; however, false-positive diagnoses remain a clinical challenge. This study aimed to evaluate the real-world diagnostic performance of a commercially available AI system and to identify factors associated with false-positive diagnoses, focusing on repeated AI evaluations and confidence stratification. Methods: This single-center retrospective study included 47 patients with 89 localized gastric lesions evaluated between March 2024 and March 2025. Endoscopic examinations were performed under white-light, non-magnified observation with repeated AI assessments of each lesion. The rates of “Consider biopsy” (B) judgments were calculated. Lesions with a B judgment rate of ≥50% were defined as AI-positive and classified into four AI confidence categories. Diagnostic performance was assessed using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Factors associated with false-positive diagnoses were analyzed using penalized logistic regression. Results: The AI system demonstrated a sensitivity of 97.6% and an NPV of 95.7%, with a specificity of 45.8%. Pathology-positive rates decreased stepwise across the four AI confidence categories (p < 0.001). Among AI-positive lesions, low regional reproducibility, lesion size ≥ 30 mm, scar, and erosion were independently associated with false-positive diagnoses. In analyses restricted to non-neoplastic lesions, lesion size ≥ 30 mm remained significantly associated with false-positive diagnosis. Conclusions: In real-world clinical practice, a commercially available AI system provides high sensitivity for early gastric cancer detection. Incorporating confidence stratification and regional reproducibility into clinical decision-making may enhance the effective use of AI-assisted endoscopic diagnosis beyond binary interpretations.